Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
1 Finally, there is a concern regarding the development of GLP-1 RA antibodies that put patients at risk of hypersensitivity reactions and reduced efficacy
Current Evidence and Availability in the UK Retatrutide remains an investigational compound with no MHRA or EMA marketing authorisation
It is moderate pressure, not the most aggressive weve seen, but the discount promise is, functionally, bait
Your GP can: Assess your current weight, BMI, and metabolic health to determine clinical need Review existing treatment options that are currently licensed and available in the UK, which may include orlistat, naltrexone/bupropion (Mysimba), semaglutide 2.4 mg (Wegovy approved by the MHRA for weight management and subject to NICE guidance on eligibility, service setting, and treatment duration), and tirzepatide (Mounjaro check current MHRA and NICE status at the time of reading, as licensing and commissioning arrangements may have been updated) Discuss eligibility for NHS Tier 3 or Tier 4 specialist weight management services , in line with NICE guidance on obesity management, where pharmacotherapy is used as an adjunct to structured lifestyle intervention Signpost you to relevant clinical trials via the Be Part of Research portal or ClinicalTrials.gov if you wish to explore participation in retatrutide research It is important to approach information about investigational medicines with appropriate caution
